RLMD Share Price | Relmada Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Relmada Therapeutics, Inc. do?

Overview:Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025)Market cap: USD 23.37 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.21Return on Equity: -337.88%Price to Book: 1.04Contact Details:Address: 880 3rd Ave Fl 12, NEW YORK NY: 10022-4730Tel: ['1 646 8763459', '1 646 8763459']Website: https://www.relmada.com/

Q: Is Relmada Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Relmada Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI remains bearish, indicating some caution. The stock has shown strong performance over the past month with a return of 148.49%, significantly outperforming the S&P 500's 2.33% return. Despite this, the longer-term returns are concerning, with a 1-year return of -52.72% compared to the S&P 500's 17.14%. Overall, while there are bullish indicators, the mixed signals suggest a cautious approach.

Results Declared: Relmada Therapeutics, Inc. has declared results on 19 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.57 M

Shareholding (Dec 2025)

FII

9.03%

Held by 33 FIIs

DII

82.23%

Held by 11 DIIs

Promoter

3.62%

How big is Relmada Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Relmada Therapeutics, Inc. has a market capitalization of 23.37 million, with net sales of 0.00 million and a net profit of -75.72 million over the latest four quarters. Shareholder's funds are at 35.52 million, and total assets are 45.82 million.

View full answer

What does Relmada Therapeutics, Inc. do?

22-Jun-2025

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for central nervous system disorders, with a market cap of $23.37 million and a recent net profit of -$18 million. The company is classified as a micro-cap and has no dividend yield.

View full answer

Who are in the management team of Relmada Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Relmada Therapeutics, Inc. includes Independent Chairman Charles Casamento, CEO Sergio Traversa, and Independent Directors John Glasspool, Paul Kelly, and Eric Schmidt, who collectively guide the company's strategic direction and operations.

View full answer

Is Relmada Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Relmada Therapeutics shows a mildly bullish trend with strong recent performance, but caution is advised due to mixed signals, including a bearish weekly RSI and concerning long-term returns.

View full answer

Compare Relmada Therapeutics, Inc. with Similar Stocks

DiaMedica Therapeutics, Inc.MediWound Ltd.Milestone Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 453 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.47

Return on Equity

-592.78%

Price to Book

47.88

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-20 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

46.27%

6 Months

267.88%

1 Year

1950.68%

2 Years

9.96%

3 Years

145.75%

4 Years

-74.79%

5 Years

-82.9%

Relmada Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-7.23%

EBIT to Interest (avg)

-97.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.21

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

46.41%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

47.88

EV to EBIT

-7.59

EV to EBITDA

-7.60

EV to Capital Employed

-99.37

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-592.78%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 12 Schemes (5.12%)

Foreign Institutions

Held by 33 Foreign Institutions (9.03%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -6.42% vs 25.79% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.30",
          "val2": "-19.10",
          "chgp": "-6.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "-0.30",
          "chgp": "166.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.90",
          "val2": "-18.70",
          "chgp": "-6.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 28.25% vs 19.03% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-59.10",
          "val2": "-83.90",
          "chgp": "29.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-57.40",
          "val2": "-80.00",
          "chgp": "28.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-20.30

-19.10

-6.28%

Interest

0.00

Exceptional Items

0.20

-0.30

166.67%

Consolidate Net Profit

-19.90

-18.70

-6.42%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -6.42% vs 25.79% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-59.10

-83.90

29.56%

Interest

0.00

Exceptional Items

0.40

0.00

Consolidate Net Profit

-57.40

-80.00

28.25%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 28.25% vs 19.03% in Dec 2024

All Annual Results

Company CV

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for central nervous system (CNS) disorders. Its product candidate includes dextromethadone (d-methadone), REL-1017, REL-1015 (LevoCap ER), REL-1028 (BuTab) and REL-1021 (MepiGel). d-methadone (dextromethadone, REL-1017) is an N-methyl-D-aspartate (NMDA) receptor antagonist. d-methadone is a new chemical entity (NCE) that is being developed for the treatment of central nervous system (CNS) diseases and other disorders. It is also being developed for the treatment of depression, ophthalmological disorders and/or other potential indications. REL-1015 (LevoCap ER) product candidate is an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol. REL-1028 is a novel oral formulations of modified release buprenorphine. MepiGel is a topical dosage form of the local anesthetic mepivacaine.

Company Coordinates

Company Details

880 3rd Ave Fl 12 , NEW YORK NY : 10022-4730

Tel: 1 646 87634591 646 8763459

https://www.relmada.com/

Registrar Details